Lanthanide-based luminescent ligand binding assays are superior to traditional radiolabel assays due to improving sensitivity and affordability in high-throughput screening while eliminating the use of radioactivity. Despite significant progress using lanthanide(III)-coordinated chelators such as diethylenetriaminepentaacetic acid (DTPA) derivatives, dissociation-enhanced lanthanide fluoroimmunoassays (DELFIAs) have not yet been successfully used with more stable chelators (e.g., tetraazacyclododecyltetraacetic acid [DOTA] derivatives) due to the incomplete release of lanthanide(III) ions from the complex. ]-a-melanocyte-stimulating hormone (NDP-a-MSH) labeled with Eu(III)-DOTA was synthesized, and the binding affinity to cells overexpressing the human melanocortin-4 (hMC4) receptor was evaluated using the modified protocol. Binding data indicate that the Eu(III)-DOTA-linked peptide bound to these cells with an affinity similar to its DTPA analogue. The modified DELFIA procedure was further used to monitor the binding of an Eu(III)-DOTA-labeled heterobivalent peptide to the cells expressing both hMC4 and cholecystokinin-2 (CCK-2) receptors. The modified assay provides superior results and is appropriate for high-throughput screening of ligand libraries.
a b s t r a c t
Lanthanide-based luminescent ligand binding assays are superior to traditional radiolabel assays due to improving sensitivity and affordability in high-throughput screening while eliminating the use of radioactivity. Despite significant progress using lanthanide(III)-coordinated chelators such as diethylenetriaminepentaacetic acid (DTPA) derivatives, dissociation-enhanced lanthanide fluoroimmunoassays (DELFIAs) have not yet been successfully used with more stable chelators (e.g., tetraazacyclododecyltetraacetic acid [DOTA] derivatives) due to the incomplete release of lanthanide(III) ions from the complex. Here a modified and optimized DELFIA procedure incorporating an acid treatment protocol is introduced for use with Eu(III)-DOTA-labeled peptides. Complete release of Eu(III) ions from DOTA-labeled ligands was observed using hydrochloric acid (2.0 M) prior to the luminescent enhancement step. ]-a-melanocyte-stimulating hormone (NDP-a-MSH) labeled with Eu(III)-DOTA was synthesized, and the binding affinity to cells overexpressing the human melanocortin-4 (hMC4) receptor was evaluated using the modified protocol. Binding data indicate that the Eu(III)-DOTA-linked peptide bound to these cells with an affinity similar to its DTPA analogue. The modified DELFIA procedure was further used to monitor the binding of an Eu(III)-DOTA-labeled heterobivalent peptide to the cells expressing both hMC4 and cholecystokinin-2 (CCK-2) receptors. The modified assay provides superior results and is appropriate for high-throughput screening of ligand libraries.
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Evaluation of ligand-receptor interactions is considered to be a fundamental screening assay in drug discovery [1] . Lanthanidebased luminescence assays provide an attractive alternative to the traditional radiolabel assays used for monitoring ligand-receptor interactions in terms of sensitivity, appropriateness for highthroughput screening, and radioactive biohazards. The superiority of lanthanide-based luminescence is due to the narrow emission bands, large Stokes shifts, limited photobleaching, and long luminescent lifetimes that allow time-resolved fluorometric assays with high sensitivity [2] [3] [4] [5] . Work in our lab has shown that the detection limit for this technology is 0.2 amol/100 lL [6] . Among the various lanthanide-based assay platforms, dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) 1 technology (Wallac/PerkinElmer Life Sciences) has been widely employed as a bioanalytical tool in both clinical and biomedical applications [7] [8] [9] [10] [11] [12] [13] [14] [15] . In DELFIA-based ligand binding assays, a ligand is labeled with a lanthanide(III) ion (e.g., Eu(III)) chelate and is competed off with test ligands or used directly for saturation binding studies [16] . The amount of specifically bound lanthanide-labeled ligand is then 0003 [17, 18] . This process enhances the lanthanidecentered luminescence by up to 10 7 -fold. The signal at 615 nm is then detected using time-resolved luminescence (TRL) with a delay time of up to 400 ls following 340 nm excitation.
DELFIA methods have been widely employed by us and others to study receptor binding of ligands labeled with derivatives of DTPA or diethylenetriaminetetraacetic acid (DTTA) chelates of Eu(-III) [6, 14, 16, 19] . For example, we previously demonstrated the use of Eu(III)-DTPA constructs to characterize and optimize ligands binding to human melanocortin-4 and d-opioid receptors. However, the eventual in vivo use of DTPA or DTTA chelates with metal ion coordination is limited due to their relative low-affinity constants for metal chelation. Heterocyclic chelators, such as tetraazacyclododecyltetraacetic acid (DOTA), are much stronger chelators; however, DOTA derivatives have not yet been used in DELFIA approaches due to the incomplete release of lanthanide(III) ions from the chelate under the traditional conditions [19] . Lanthanide(III) complexes formed with DOTA and their derivatives have received intense scrutiny in a wide range of biomedical applications, including magnetic resonance imaging (MRI), paramagnetic chemical exchange saturation transfer (PARACEST) MRI, and positron emission tomography [20] [21] [22] [23] . DOTA and its derivatives offer the highest thermodynamic and kinetic stability, with a wide selection of metal ions among the commonly used polyaminocarboxylic acid chelators (stability constants of 25.3 and 22.4 for Gd(III)-DOTA and Gd(III)-DTPA, respectively) [23] [24] [25] . DOTA complexes are more suitable for in vivo radiopharmaceutical applications under conditions where the clearance of the contrast agent is relatively slow [26] . As a part of our ongoing research, we are designing and developing DOTA-labeled ligands for biomedical applications with Gd(III)-and In(III)-based chelation chemistries for MRI and gamma ray detection, respectively. This article discusses the development and evaluation of a modified DELFIA technology based on an acid treatment protocol for the use of lanthanide(III)-DOTA-labeled ligands in whole cell ligand-receptor binding studies. ]-a-melanocyte-stimulating hormone (NDP-a-MSH) [27] to HEK293 cells expressing the human melanocortin-4 (hMC4) receptor [28] as a model system where one of the carboxylic acid groups of DOTA or DTPA is used for ligand coupling. DTPA-labeled compounds were used for comparison with the traditional DELFIA. Furthermore, the modified DELFIA protocol was used to demonstrate the targeting of a heterobivalent ligand to two different combinations of cell surface receptors as a proof-of-study where heteromultivalency is used to crosslink multiple receptors [29] . The Eu(III)-DOTA-labeled heterobivalent ligand was constructed from analogues of NDP-a-MSH peptide and the cholecystokinin-6 (CCK-6) peptide targeted to cells expressing both hMC4 and CCK-2 receptors.
The requirement of an acid treatment procedure for a complete release of lanthanide(III) ions from DOTA derivative is shown in Fig. 1 
Materials and methods

General chemistry methods
N-a-9-Fluorenylmethoxycarbonyl (Fmoc)-protected amino acids, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt), and the bifunctional polyethyleneglycol linker PEGO (19-amino-5-oxo-3,10,13,16-tetraoxa-6-azanonadecan-1-oic acid) were purchased from SynPep (Dublin, CA, USA) or Novabiochem (San Diego, CA, USA). Rink amide Tentagel S resin was acquired from Rapp Polymere (Tubingen, Germany). DOTA-NHS ester (N-hydroxysuccinimide ester) was purchased from Macrocyclics (Dallas, TX, USA). DTPA dianhydride and Fmoc-PEG9 (8-amino-3,6-dioxaoctanoic acid) were purchased from Aldrich (Milwaukee, WI, USA) and Peptides International (Louisville, KY, USA), respectively. For the N- 
Ligand synthesis
The ligands were synthesized manually as described previously using -Fmoc amino acid, 3 equiv. of HBTU, and 6 equiv. of DIEA in DMF) for 3 h. If the second coupling did not result in a negative Kaiser test, the resin was washed with DMF and the rest of the amino groups were capped with 50% acetic anhydride in pyridine for 10 min. When the coupling reaction was finished, the resin was washed with DMF and the same procedure was repeated for the next amino acid until all of the amino acids in the sequence were attached. Attachment of PEG9 or PEGO linkers was performed using DIC/ HOBt activation (3 equiv. of N a -Fmoc-PEG9 or Fmoc-PEGO, 3 equiv. of HOBt, and 3 equiv. of DIC).
Aloc cleavage
The orthogonal protecting Aloc group of lysine was cleaved as follows for the attachment of PEG9 linker in heterobivalent ligand. The resin was washed with dichloromethane (DCM) and then flushed with argon for 10 min. A cleavage mixture of dimethylbarbituric acid (5 equiv.) and Pd(TPP) 4 (0.2 equiv.) in DCM (0.5 M solution) was flushed with argon and injected into the syringe. The reaction mixture was stirred for 30 min and then repeated. The resin was washed with DMF, 10% DIEA in DMF, DMF, 2% sodium diethyldithiocarbamate trihydride, 10% DIEA in DMF, and DMF.
DTPA and DOTA attachment
The DTPA chelator was attached to the N terminus of resinbound PEG9-NDP-a-MSH resin. After Fmoc removal, the free amine resin was washed with dimethyl sulfoxide (DMSO). DTPA dianhydride (10 equiv.) and HOBt (30 equiv.) were dissolved in 1 mL of dry DMSO at 50°C and stirred for 20 min at room temperature. The reagent mixture was then injected into the syringe reactor. The resin was stirred overnight and then washed with DMSO, THF, 20% aqueous THF, THF, 5% DIEA in THF (5 min), and THF. DOTA was attached to resin-bound PEG9-NDP-a-MSH resin and N e -amine lysine side chain of Ac-MSH(7)-PEGO-[ProGly] 6 -Lys(PEG9)-PEGO-CCK(6) resin. DIEA (10 equiv.) and DOTA-NHS ester (3 equiv.) in DMF were injected into the free amine resin and stirred overnight. The resin was washed with DMF, THF, and DCM.
Cleavage of ligands from the resin
The resin was washed with DMF, THF, and DCM. A cleavage mixture (10 mL/g resin) consisting of TFA (91%), water (3%), 1,2-ethanedithiol (3%), and thioanisole (3%) was injected into the resin and then stirred for 4 h at room temperature. The solution was filtered off, and the resin was washed with TFA (2 Â 3 min). Collected filtrates were concentrated by a stream of nitrogen, and the product was precipitated by cold ether. The peptide pellets were washed three times with cold ether, dried, dissolved in 1.0 M acetic acid, and lyophilized.
Eu(III) labeling of peptides
The lyophilized peptide was dissolved in 0.1 M ammonium acetate (pH was adjusted to 8.0 with aqueous 0.1 M NH 4 OH) and treated with 3 equiv. of EuCl 3 Á6H 2 O in water. The reaction mixture was stirred at room temperature overnight. The excess of Eu(III) chloride and ammonium salts was removed using a SEPAC C-18 reverse-phase column with repetitive washing (20 mL of HPLCgrade water). The final product was eluted using 50% aqueous acetonitrile (4 mL) and lyophilized.
Cell culture HEK293 cells were engineered to overexpress the hMC4 receptor as described previously [28] . The coding region of the hMC4 receptor gene was expressed in pcDNA3.1 (product no. V790-20, Invitrogen, Carlsbad, CA, USA). HEK293 cells expressing both hMC4 and CCK receptors were used for heterobivalent binding studies. All cells were maintained under standard conditions (37°C and 5% CO 2 ) and were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The dual expressing cells maintained were under selection in the above medium containing zeocin (100 mg/mL) and geneticin (0.4 mg/mL). At 90% cell confluency (verified by microscopy), cells were harvested for plating in 96-well plates for performing the receptor-ligand binding assays.
Eu(III)-based ligand binding assays
Cells were plated in black Costar 96-well plates (product no. 3603) at a density of 20,000 cells/well and were allowed to grow for 3 days. The HEK293 cells adhere to the plastic reasonably well; however, if weakly attaching cells are used, the wells can be coated with extracellular matrices or polylysine to improve cell retention during the assay incubation period. On the day of the experiment, medium was aspirated from all wells prior to the addition of the ligands to be tested. Ligands were diluted in binding medium (DMEM, 1 mM 1,10-phenanthroline, 200 mg/L bacitracin, 0.5 mg/ L leupeptin, and 0.3% bovine serum albumin [BSA] ) and samples were tested in quadruplicate unless otherwise noted. Saturation binding assays were carried out as follows. Increasing amounts of Eu(III)-labeled peptides were added to cells and incubated for 1 h at 37°C. Following the incubation, cells were washed three times with wash buffer (50 mM Tris-HCl, 0.2% BSA, and 30 mM NaCl). For our experiments, the medium was carefully replaced manually using a vacuum manifold. It is important to make certain that cells are not released during the washing maneuver. Microscopic analysis of the aspirate can provide a simple evaluation of cell release in control experiments. After the cell wash period, no additional removal of medium from the wells can occur because both the enhancement solution and acid treatment are cytotoxic. When testing Eu(III)-DTPA-labeled ligands, the enhancement solution (product no. 1244-105, PerkinElmer) was added directly to the wells (100 lL/well) after washing and the plates were incubated for at least 30 min at 37°C prior to reading. The plates were read on a Wallac Victor 3 instrument using the standard Eu(III) TRL measurement (340 nm excitation, 400 ls delay, and emission collection for 400 ls at 615 nm). For Eu(III)-DOTA-labeled ligands, 2.0 M HCl (50 lL/well) was added after the wash step and the plates were incubated at 37°C for 2 h. The samples were then neutralized using 2.0 M NaOH (55 lL/well), followed by the enhancement solution (115 lL/well).
The analysis procedure was carried out as described for Eu(III) TRL measurements. Competitive binding assays were carried out using variable concentrations of nonlabeled ligand (50 lL/well) and a fixed concentration of Eu(III)-labeled ligand (10 nM, 50 lL/well) and using otherwise identical conditions provided above. Data were analyzed with GraphPad Prism software using appropriate nonlinear regression analyses.
Results
Synthesis of Eu(III)-labeled ligands
All peptides were synthesized using standard solid-phase technology, whereas Eu(III) labeling was performed in the solution phase. A representative synthetic scheme of Eu(III)-DOTA-PEG9-NDP-a-MSH is shown in Fig. 2 . Eu(III) chelators (DTPA and DOTA) were attached through a PEG9 semirigid linker to the a-amino terminal of serine (in NDP-a-MSH) or to the e-amino group of lysine (in the heterobivalent ligand). A previously reported procedure was adapted for the attachment of DTPA to NDP-a-MSH where an in situ di-HOBt ester of DTPA was formed before the coupling with the free amino group of the resin-bound ligands [6] . Activated DOTA-NHS ester was used for the coupling of DOTA chelator to the PEG9 linker.
MSH-7, a heptapeptide fragment of NDP-a-MSH, and CCK-6, a hexapeptide fragment of [Nle 28 DOTA-labeled heterobivalent ligand was used in the current study, as shown in Fig. 3 
Optimization of the modified DELFIA protocol
We quantitatively evaluated the Eu(III) ion concentration of both DOTA-and DTPA-labeled NDP-a-MSH, as shown in Fig. 4 . Without the acid treatment, we were able to detect only 0.4 nM Eu(III) ions in a predetermined solution of 10 nM Eu(III)-DOTA-labeled NDP-a-MSH. In contrast, 10 nM Eu(III) was detected after acid treatment. Complementary experiments performed with or without acid treatment gave 10 nM Eu(III) ions in DTPA-labeled ligands, in agreement with our qualitative assessment shown in Fig. 1 .
The modified DELFIA protocol consists of additional acidification and neutralization steps prior to the addition of the enhancement solution. HCl was chosen to acidify the Eu(III)-DOTAlabeled ligands because excess Cl À ions do not interfere with the formation of Eu(NTA) 3 (TPPO) 2 complex or the luminescent signal. The conditions (concentrations, time, and temperature) were optimized for the complete release of Eu(III) ions (Fig. 5) . By increasing the acid strength or the incubation time, Eu(III) ions are released from DOTA according to a mechanism similar to first-order kinetics (see Supplementary material). After carefully analyzing the acid strengths, we decided to use 2.0 M HCl acid for the acidification step. The optimized volume of 2.0 M HCl and the incubation time with the acid are 50 lL and 2 h, respectively (Fig. 5) .
The formation of Eu(NTA) 3 [6] . Here we performed a systematic study using HCl acid. Fig. 6 shows the measured Eu(III)-centered luminescent intensity at different pH values. The intensity drops dramatically below pH 2.0. This may be due to the instability of the Eu(NTA) 3 (TPPO) 2 complex and the micellar structures under strong acidic conditions. Especially the formation of lanthanide(III)-b-diketonates is not favorable under extremely acidic conditions. The maximum luminescent intensity was observed in the pH range of 3.0 to 5.0, and a slight but noticeable decrement of the intensity was evident at higher pH values. At higher pH conditions, the formation of lanthanide-oxo and -hydroxo species is favorable with lower intensities due to the quenching of Eu(-III)-based luminescence in the presence of O-H-type bonds. Therefore, the final pH of the samples was adjusted back to approximately 4.0 using 2.0 M aqueous NaOH before adding the enhancement solution.
We revisited the concentration and volume dependence of the enhancement step due to the differences in the matrix used for Eu(III)-DOTA-labeled ligands compared with that used for DTPA. Fig. 7 indicates enhancement volume and time dependence in the presence of Eu(III)-DOTA-NDP-a-MSH with 2.0 M HCl and 2.0 M NaOH. According to Fig. 7B , the samples should be incubated for at least 30 min to fully develop the luminescent intensity. This incubation time is consistent with our prior observations using Eu(III)-DTPA-labeled peptides [6] . In the case of DTPA, the enhancement solution is used both to release Eu(III) ions from the DTPA chelator and to provide photoactive chelators, that is, NTA. On the other hand, HCl is also used to release Eu(III) ions from DOTA chelator prior to the addition of the enhancement solution. Therefore, the observed similar enhancement times indicate that the overall formation of the photoactive Eu(III) complexes with the micellar structure is the rate-determining step in lanthanidebased dissociation-enhanced assays. A significant level of the luminescence was observed within minutes after the addition of the enhancement solution. However, the optimal signal was achieved after the incubation of the plates for 30 min. Part of this must be due to the diffusion control of the enhancement solution and the formation of the micellar structures in the presence of TOPO. The addition of 115 lL of the enhancement solution was sufficient to detect the highest luminescent signal intensity in Eu(III)-DOTA-labeled ligands. The value was higher than that observed for DTPAbased ligands (100 lL) due to the presence of NaOH.
Cell binding assays using Eu(III)-DOTA-labeled NDP-a-MSH
The modified DELFIA protocol was used to evaluate the binding of Eu(III)-DOTA-labeled NDP-a-MSH to HEK293 cells overexpressing the hMC4 receptor. As a comparison, the traditional DELFIA protocol was also carried out using Eu(III)-DTPA-labeled analogue on the same cell line using an otherwise identical cell preparation and washing conditions. The saturation binding curves using Eu (-III) (38 and 49 nM, respectively) . Therefore, the modified DELFIA protocol (using Eu(III)-DOTA-labeled ligand) produced identical results to the traditional DELFIA (using DTPA analogue) in a whole cell binding assay using 96-well plates. The observed K d value of the Eu(III)-DTPA-labeled NDP-a-MSH through a PEG9 linker (in this study) was slightly higher than that previously observed using e-aminocaproic acid as the linker (K d = 18.8 nM) [6] . This might be due to the interference of different linker structures on ligandreceptor binding.
Competitive binding assays against NDP-a-MSH were performed for both Eu(III)-DTPA-and Eu(III)-DOTA-labeled ligands (Fig. 9) . The IC 50 values of both Eu(III)-DTPA-and Eu(III)-DOTA-labeled ligands were similar (0.079 and 0.055 nM, respectively). Hence, the presence of the Eu-DOTA chelate with NDP-a-MSH did not significantly alter its binding affinity compared with that of DTPA. 
Saturation binding of Eu(III)-DOTA-labeled MSH/CCK heterobivalent ligand
To further verify the use of the modified DELFIA, the Eu(III)-DOTA-labeled heterobivalent ligand containing both MSH and CCK was evaluated in a saturation binding assay. We previously showed that the heterobivalent ligands can bind to multiple receptors, leading to enhanced avidity and selectivity [29] . Fig. 10 shows the saturation binding curve of Eu(III)-DOTA-labeled heterobivalent ligand to HEK293 cells overexpressing both hMC4 and CCK-2 receptors. Nonspecific binding was determined in the presence of 10 lM NDP-a-MSH and CCK (8) . The K d value of the labeled ligand was found to be 10 nM. This value is consistent with the K d value obtained in a single cell-level fluorescence binding assay carried out using Cy5-labeled analogue (data not shown).
Evaluation of assay quality and validity of the modified DELFIA The modified DELFIA assay quality was assessed using both a Z 0 factor and signal-to-noise ratio (S:N) analysis. S:N was calculated by taking into account variation of both the control and the responding sample population using the following equation (see Ref. [30] for description and testing), with an S:N value of 2.5 generally accepted as indicating excellent assay sensitivity:
where l is the mean signal, r is the standard deviation, p represents positive control, and n represents negative control. This parameter was evaluated for Eu(III)-DOTA-and Eu(III)-DTPA-labeled NDP-a-MSH ligands in their competitive and saturation binding assay platforms (see Supplementary material). The calculated S:N values of DOTA-and DTPA-labeled ligands near their IC 50 values are 15.4 and 8.9, respectively. Consequently, DOTA derivatives, using our modified DELFIA protocol, can be used in receptor-ligand binding assays with a relatively higher S:N value. The Z 0 factor is a standard approach to evaluate the sensitivity of a small preliminary assay for its potential use as a screening assay involving a large number of comparisons such as gene or protein arrays [31] . The Z 0 factor was calculated according to
The calculated Z 0 factor values of DOTA-and DTPA-labeled ligands near their IC 50 values are 0.79 and 0.64, respectively (see Supplementary material), with a Z 0 factor greater than 0.5 indicating adequate assay sensitivity.
We evaluated the detection limits of Eu(III)-DOTA-and Eu(III)-DTPA-labeled NDP-a-MSH using two different approaches, and their S:N values were evaluated (see Supplementary material). Our results confirm that the modified DELFIA can be used to detect attomoles of Eu(III) ions per well in a 96-well plate using Eu(III)-DOTA NDP-a-MSH.
Discussion
Traditional DELFIA technology has its limitations for use with more stable derivatives of lanthanide chelators such as DOTA due to the incomplete release of Eu(III) ions required for detection. To overcome this problem, we have introduced a modified and optimized DELFIA protocol where Eu(III)-DOTA-labeled ligands were used to evaluate the ligand-receptor interactions. In the traditional DELFIA protocol, the essential steps involve incubation of the cells with the labeled ligands, wash steps to remove the unbound ligands, incubation with the enhancement solution, and TRL measurements. The modified protocol consists of additional acidification and neutralization steps prior to the enhancement step.
Strong acidic conditions with pH lower than 2.0 are necessary for a complete release of Eu(III) ions from DOTA derivatives. Here 2.0 M HCl was chosen for the acidification step, and the volume of the acid and the incubation time were optimized. Subsequent neutralization of the medium was essential because the Eu(III)-centered luminescence was not observed under strong acidic conditions and the enhancement solution by itself is not capable of raising the pH to its optimal value (3.0-5.0) to detect the maximum signal. Therefore, the final pH of the samples was adjusted back to neutral pH or higher using 2.0 M NaOH before the enhancement step. As such, the enhancement solution can now readjust the pH of the samples to their optimal value for maximum signal detection.
Our attempts to use moderately volatile acids such as TFA were unsuccessful. An HCl acid concentration of 2.0 M was chosen to successfully release Eu(III) ions within hours and considering the practicability of adjusting the pH back to the optimal value. Higher acid concentrations such as 5.0 M can be used to release Eu(III) ions within minutes, but the readjustment of the pH was more variable. Many strong acids can serve our purpose. However, an acid must be selected such that the counterions will not interfere with the formation of the lanthanide(III) luminescent complex and its micellar structure. Lastly, the neutralization must be tested before the enhancement step for higher sensitivity.
The use of lanthanide-based binding assays has greatly improved the sensitivity of receptor-ligand measurements. With the advent of synthetic procedures for making potent lanthanidelabeled ligands, the need for radiolabeled ligands is diminishing. Moreover, the use of TRL measurements with lanthanides provides a method for substantially decreasing background noise and, thereby, improving S:N ratios and assay sensitivity into the attomolar range. Thus, the modified DELFIA provides a platform to explore novel ligands with highly stable lanthanide chelators such as DOTA for evaluating ligand-receptor interactions. Importantly, the developed protocol is highly reproducible, easy to set up, and amenable to high-throughput screening.
